Sublingual Apomorphine (APL-130277) for the Acute Conversion of off to on in Parkinson's Disease
Introduction: OFF episodes negatively impact quality of life in patients with Parkinson's disease (PD). There remains a need for an acute, effective, noninvasive treatment. Background: APL-130277 is a sublingually administered apomorphine oral strip. Methods: The authors conducted a phase 2, open-label, proof-of-concept study. Patients presented to clinic in the morning in the practically defined OFF state and were dosed with APL-130277 10 mg. Assessments of OFF or ON state and MDS-UPDRS part III were conducted predose and at 15, 30, 45, 60, and 90 minutes. If a full ON was not achieved within 3 hours, the dose was increased in 5 mg increments until a full ON was achieved or to a maximum dose of 30 mg. Patients could be dosed up to two times a day over 3 days. Patients were pretreated with trimethobenzamide for 3 days, which was continued during the study. Results: Of 19 patients, 15 (78.9%) achieved a full ON response. All 15 achieved a full ON response within 30 minutes and 6 of the 15 patients (40.0%) achieved a full ON response within 15 minutes. The mean (SD) duration of ON was 50 (19.4) minutes. Of the 15 patients, 9 (60.0%) remained fully ON for ‰¥90 minutes. There were no discontinuations as a result of an adverse event. The most common adverse events were dizziness (36.8%), somnolence (31.6%), and nausea (21.1%). Conclusion: This was the first study of a new sublingual apomorphine formulation in PD patients. In this open-label study, APL-130277 appeared to provide a convenient, rapid, and reliable method for treating OFF episodes.
Medical Subject Headings
Digital Object Identifier (DOI)
Hauser, Robert A.; Olanow, C. Warren; Dzyngel, Bruce; Bilbault, Thierry; Shill, Holly A.; Isaacson, Stuart; Dubow, Jordan; and Agro, Albert, "Sublingual Apomorphine (APL-130277) for the Acute Conversion of off to on in Parkinson's Disease" (2016). Neurology. 238.